NCT02048618已完成2 期
Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Galapagos NV
- 入组人数
- 175
- 试验地点
- 62
- 主要终点
- Percentage of subjects achieving clinical remission at Week 10
研究概览
简要总结
- 180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition to their stable background treatment.
- During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood and stool (Pharmacodynamics) will be determined. Also, the effects GLPG0634 administration on subjects' quality of life will be evaluated.
详细描述
- 180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated when taking GLPG0634 or matching placebo once daily in addition to their stable background treatment. The population will include 50% anti-TNF naïve patients and 50% of subjects previously exposed to anti-TNF.
- The study will consist of 2 parts, with total treatment duration of 20 weeks. Randomisation in Part 1 will be stratified according to subject's previous anti-TNF exposure, C-reactive protein (CRP) level at Screening and oral corticosteroid use at Day -1. However, at Week 10, subjects will be re-randomized automatically and stratified according to the subject's clinical response (reduction of Crohn's Disease Activity Index (CDAI) of 100 points), previous anti-TNF exposure and corticosteroid use at Day -1 to receive GLPG0634 200 mg q.d., 100 mg q.d. doses, or matching placebo q.d. in a blinded fashion. In Part 2, all will continue the study until Week 20.
- As efficacy parameters, the ability to achieve clinical response or remission, endoscopic response & remission as well as mucosal healing with GLPG0634 given once daily compared to placebo will be evaluated after 10 weeks of treatment. In subjects who achieved clinical remission at Week 10, maintenance of the remission will be assessed during Part 2 of the study.
- During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood and stool (Pharmacodynamics) will be determined. Also, the effects of different doses and dose regimens of GLPG0634 administration on subjects' quality of life will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects between 18 and 75 years
- •Documented history of ileal, colonic, or ileocolonic CD
- •CDAI score ≥ 220 to ≤ 450
- •Evidence of active inflammation as demonstrated by endoscopic confirmation of active disease
- •Subjects previously not exposed to anti-TNF treatment (TNF-naïve) or subjects previously exposed to anti-TNF therapy at a registered dose, that has been discontinued at least 8 weeks prior to Screening and deemed by the treating physician as a primary or secondary non-responder or intolerant (TNF-experienced)
- •Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day), mesalazine, olsalazine, CD-related antibiotics and probiotics at stable dose is allowed
- •Previous exposure to immunomodulators is permitted, but must be discontinued
- •Haematology and biochemistry lab parameters within predefined ranges as stated in the protocol
排除标准
- •Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC
- •Stoma, gastric or ileoanal pouch, procto- or total colectomy, symptomatic stenosis or obstructive strictures, history of bowel perforation, (suspected) abscess; actively draining fistulae
- •Subject who has had surgical bowel resections within the past 6 months, short bowel syndrome or is receiving tube feeding, defined formula diets, or parenteral alimentation
- •Subject with positive Clostridium difficile toxin stool assay or evidence of any other gastrointestinal infection
- •Subject who has received non-permitted IBD therapies within specified timeframes, depending on the medication, as stated in the protocol
- •Subject with a (previous history of) dysplasia of the gastrointestinal tract
- •Concurrent gastro-intestinal malignancy or a history of cancer elsewhere
- •History of lymphoproliferative disease
- •Known active infection of any kind, current therapy for chronic infection or history of specific infections as stated in the protocol
- •Subject who is pregnant, lactating or not willing to maintain highly effective birth control methods during the course of the study and 12 weeks thereafter
研究组 & 干预措施
GLPG0634 200 mg QD
Experimental
2 tablets of 100 mg GLPG0634 in the morning
干预措施: GLPG0634 (Drug)
GLPG0634 100 mg QD
Experimental
1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
干预措施: GLPG0634 (Drug)
GLPG0634 100 mg QD
Experimental
1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
干预措施: Placebo (Drug)
Placebo QD
Placebo Comparator
2 placebo tablets in the morning
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of subjects achieving clinical remission at Week 10
时间窗: Week 10
Percentage of subjects achieving clinical remission as defined by a Crohn's Disease Activity Index score \< 150 points
次要结局
- Percentage of subjects achieving mucosal healing at Week 10(Week 10)
- Change from Screening in endoscopic score(Week 10)
- Change from Baseline in Subjects' Quality of Life (based on the Inflammatory Bowel Disease Questionnaire (IBDQ) questionnaire score)(Up to Week 20)
- Percentage of subjects achieving endoscopic remission at Week 10(Week 10)
- The number of subjects with abnormal lab tests(From screening up to 2 weeks after last dose)
- The number of subjects with abnormal vital signs(From screening up to 2 weeks after last dose)
- The change versus Baseline in levels of immune- and inflammation-related parameters in whole blood and serum(Up to Week 20)
- Change from Screening in histopathology biopsy score(Week 10)
- The number of subjects with adverse events(From screening up to 2 weeks after last dose)
- Percentage of subjects achieving clinical response(Up to Week 20)
- The number of subjects with abnormal ECG(From screening up to 2 weeks after last dose)
- Percentage of subjects achieving clinical remission(Up to Week 20)
- Percentage of subjects achieving endoscopic response at Week 10(Week 10)
- Change from Baseline in Crohn's Disease Activity Index score(Up to Week 20)
- The change versus Baseline in levels of faecal calprotectin(Up to Week 20)
- The change versus Baseline in microbial communities in stool samples(Up to Week 10)
- The plasma levels of GLPG0634 and its metabolite(Up to Week 20)
研究者
研究点 (62)
Loading locations...
相似试验
撤回
2 期
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's DiseaseCrohns DiseaseCrohn's DiseaseNCT04151225GlaxoSmithKline
已完成
2 期
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's DiseaseCrohn's DiseaseNCT01276509Shire265
终止
2 期
A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's DiseaseCrohn DiseaseNCT04978493Boehringer Ingelheim49
已完成
2 期
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF TherapyCrohn's DiseaseNCT00771667Centocor, Inc.526
已完成
1 期
Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending DoseInflammatory Bowel DiseaseNCT00868660Zealand Pharma66